EGFR and lung carcinoma: Conversely, Chiang et al. found that mTOR signalling contributes to metabolic reprogramming in erlotinib (EGFR inhibitor) resistant lung cancer cells and strongly correlates with poor clinical outcomes of EGFR-mutated lung cancer patients [96].